Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABA-101 in Progressive Multiple Sclerosis
NCT06566261Phase 1Active, not recruiting
- Sponsor
- Abata Therapeutics
- Start
- Sep 2024
- Primary completion
- Feb 2026
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABA-101 in multiple sclerosis (MS) (2 arms), sponsored by Abata Therapeutics. Primary endpoint: Incidence of adverse events. Started Sep 2024; status: active, not recruiting.
02
Drugs
ABA-101
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06566261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566261.